Based on the role of the FGF1–FGFR signaling axis in cancer, a number of novel drugs targeting this pathway have been developed and are recently undergoing preclinical and clinical trials in various FGFR-related tumors [7,8]. This evidence concerns the gene FGF1 and cancer.